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Abstract. Metabolic syndrome is a conditions caused by metabolic abnormalities include 
central obesity, atherogenic dyslipidemia, hypertension, and insulin resistance. HbA1c 
examination is required to study the long-term glycemic status and to prevent diabetic 
complications of metabolic syndrome. The purpose of this study is to determine the efficacy of 
black cumin seed (Nigella sativa) oil and hypoglycemic drug combination to reduce HbA1c 
level in patients with metabolic syndrome risk. This research performed using an experimental 
randomized single - blind controlled trial design. A total of 99 outpatients at the Jetis I Public 
Health Center, Yogyakarta, Indonesia with metabolic syndrome risk were divided into three 
groups: The control group received placebo and two treatment groups received black seed oil 
orally at  dose of 1.5 mL/day and 3 mL/day, respectively, for 20 days. The clinical conditions 
such as blood pressure, pulse rate, BMI, blood glucose serum and HbA1c levels were 
examined on day 0 and 21. The results obtained were analyzed with one-way ANOVA test. 
The mean of HbA1c levels of all groups before treatment was higher than the normal values 
and there was no significant difference in HbA1c value on day 0. Administration of 1.5 and 3 
mL/day of black seed oil for 20 days decreased (p<0.05) HbA1c levels. It can be concluded 
that administration of black cumin seed oil and hypoglycemic drug combination for 20 days in 
patients at risk of metabolic syndrome may reduce to HbA1c levels. 
Keywords: metabolic syndrome outpatients, black cumin seed oil, HbA1c, clinical test
1. Introduction 
One of the public health problems in Indonesia is metabolic syndrome (MS). MS is a major risk 
factor for vascular and degenerative diseases, including cancer [1-3]. In Indonesia, MS 
prevalence varies based on age, gender, and region between 11 and 24.7% [4, 5].  One of the 
MS diseases, diabetes mellitus, is associated with the complications of various chronic and fatal 
diseases. Diabetes complications cause 50% and 30% of deaths due to coronary heart disease 
and kidney failure respectively. Diabetes also causes disability, in which 30% of patients 
experienced blindness due to retinopathy complications and 10% of them had to undergo leg 
amputation [6]. Diabetes mellitus is also associated with sudden death incidence in the 
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community  [7]. Epidemiologically and clinically, it has been demonstrated that angiopathic 
complication is associated with high hemoglobin A1c (HbA1c) levels. 
HbA1c levels considered safe are about 6.5-7%. It is one of the glycosylated proteins to form 
HbA1c. Glycosylation occurs spontaneously in the circulation and will increase when blood 
glucose levels are high [2]. HbA1c was the average blood glucose level for 2-3 months [2, 
8]. More than 50% of diabetes mellitus patients experience failure to control blood glucose 
levels that lead to HbA1c levels abnormalities (>7%) [9]. High blood glucose or HbA1c levels 
causes oxidative stress that damages blood vessels and triggers vascular endothelial death [10, 
11]. HbA1c is formed from a bond of glucose with an amide group on the valine amino acid at 
the end of the Hb globulin beta chain. If this condition is prolonged, irreversible advanced 
glycosylation end products (AGE) will be formed on the walls of blood vessels that may be 
potentially pathogenic and lead to diabetic complications [12, 13]. Increased AGE results in 
cellular and tissue oxidative stress, causing damage to tissues and blood vessel cells, especially 
the endothelium tissue and generating an inflammatory reaction [10, 14].  
Oral hypoglycemic drugs (OHOs), which are standard therapy for controlling blood glucose 
in DM patients, are estimated to be only capable of lowering HbA1c by approximately 0.5-2%, 
depending on the type of individual OHO drugs [9]. Therefore, it is often necessary for 
additional or complementary therapies to improve the achievement of ideal HbA1c levels of 
<7% [8, 15]. It is expected that a combination of high antioxidant food diet and OHOs therapy 
will lower HbA1c levels [12, 16]. Black cumin seed (Nigella sativa) oil (BCSO) has empirically 
been used as a dietary supplement, antioxidant medicinal ingredients, and 
immunomodulators.  BCSO contains thymoquinone, nigellone, thymohydroquinone, 
dithymoquinone, thymol, carvacrol, nigellcine, nigellimine-N-oxide, nigellidine and alpha 
hedrin which are empirically and laboratorically antioxidative [17]. In preclinical studies, it has 
been demonstrated that BCSO administration on Danforth's short tail (SD) mice induced by 
alloxan can prevent damage to the pancreas and the liver by increasing the p53 gene expression 
[18]. It is safe and well-tolerated in phase 1 trial [19]. BCSO administration as an adjunctive 
therapy in hyperlipid and hyperglycemic patients at hospital could significantly reduce total 
cholesterol, LDL, and fasting blood glucose levels. However, the effect of BCSO on HbA1c in 
patients with risk of metabolic syndrome at Public Health Center has never been 
investigated. Therefore, this study aims to investigate the effect of black cumin seed oil on 
HbA1c in Public Health Center outpatients with the risk of metabolic syndrome [20]. 
 
2. Materials and Methods 
This study was a randomized control trial with two dose levels. The number of samples was 
determined according to the phase 2 clinical trial guidelines, where the sample number was 80-
300 volunteers. A total of 99 subjects with metabolic syndrome were divided into three groups, 
33 subjects of each which would receive  BCSO at dose of 1.5 mL/day and 3 mL/day for 20 
days. 
Research subjects were outpatients at risk of metabolic syndrome at Jetis I Public Health 
Center, Bantul, Yogyakarta, Indonesia. The inclusion criteria were male or female patients aged 
>18 years old, willing to become research volunteers proven by voluntarily signing of informed 
consent, having been diagnosed with diabetes mellitus or dyslipidemia or hypertension with or 
without central obesity and having become the outpatient at Jetis 1 Public Health Center at least 
for three months. Exclusion criteria were drop out volunteers, pregnant women, taking NSAID 
medications and immunomodulatory supplements, allergic with black cumin seed oil, having a 
history of chronic kidney disease and cancer, undergoing hyperthyroid and diabetic ulcers 
therapy and active pulmonary TB patients. For 20 days, groups 1 and 2 were given 1.5 mL/day 
and 3 mL/day of BCSO soft capsule, respectively, while group 3 acts as a placebo group.  This 
clinical trial research protocol has been reviewed and endorsed by the medical research ethics 
committee of the Faculty of Medicine and Health Sciences, Universitas Muhammadiyah 
Yogyakarta, Indonesia. The selection of prospective research subjects was based on outpatient 
computer database at the Public Health Center. From the database, it was found that from May 
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to October 2016, there were 650 patients at risk of metabolic syndrome. The patients’ medical 
records containing information about hypertension, dyslipidemia, or diabetes mellitus with or 
without obesity were listed and screened to ensure that the medical records data met the 
inclusion criteria. A total of 120 patients met the criteria, and they were subsequently designated 
as subject candidates. All prospective subjects were gathered and briefed on general research 
objectives and benefits and the specific benefits and consequences of participating as research 
volunteers. Candidates who were willing to participate in the study were required to give 
consent by signing the informed consent. A total of 112 prospective subjects who have signed 
then informed consent then underwent physical and laboratory checks. Based on the baseline 
examination, 13 patients met the exclusion criteria. 
The research was conducted at Jetis I Public Health Center, Bantul, Yogyakarta for 10 
months from March to December 2016. The research instrument used was a spectrophotometer 
to measure blood glucose level, while the test material used was BCSO soft capsules containing 
standardized black cumin seed oil with a composition of: 2.72% thymoquinone and 0.15% 
caprylic fatty acid, caprat 0.1%, laurat 0.18%, miristat 12.27%, palmitate 0.28%, stearate 
7.99%, oleate 0.07%, linoleat 2.85%, eicosanoate 3.15%, eicosenat 0.25%, eicosadienoate 
0.03%, arachidonate 0.03%, eicopentanoate 0.03%, behenat 0.06%, docohexanoate 0.04%, 
0.02% teracosanoate and placebo in the form of empty capsules. 
A total of 99 subjects were divided into three simple randomized groups (with a lottery 
system). Randomization was done manually by comparison between groups of 1:1:1. Random 
grouping was done by pharmacist with multiple lot sweepstakes. All subjects were recorded 
based on sequence number and then divided into three groups: treatment group 1, treatment 2 
and placebo group. The drawing was done by taking number 1, 2, and 3. The number obtained 
by the first drawer acts as the treatment group 1, the number obtained by the second drawer as 
the treatment group 2, and the number obtained by the last drawer as the treatment group 3. The 
members of each group were selected using a multiple of 3 of the lottery number obtained. If the 
first lottery gets the number 1, then the members of the treatment group 1 were 4, 7, 10 and so 
on until the quota of 33 patients was reached. The same method applied to treatment group 2 
and treatment group 3 (placebo). 
The treatment given to the subjects was soft capsule (SC) of BCSO with doses of 1.5 and 3 
mL/day or placebo.  BCSO capsules were prepared by the pharmaceutical industry with Good 
Manufacturing Practices (GMP) certificate. The material was tested to examine the heavy metal 
content and standardization of the thymoquinone content. The capsule administration was done 
by doctors at Jetis I Public Health Center. The examination of post-treatment clinical conditions 
was done also by the doctors every two weeks at Public Health Center. Specifically trained 
teams were required to make visits to patients' homes twice per week to check blood pressure, 
pulse, and body mass index, and monitor unexpected reactions and medication compliance. The 
analysts and research personnel have been trained in the procedures as written in the protocol. 
Vital signs, Random Blood Glucose (RBG) and HbA1c levels were examined on day 0 (to 
serve as baseline data) and 21. The peripheral blood was taken from the cubital vein by the 
previously trained Public Health Center laboratory analyst. From the collected blood, RBS and 
HbA1c were measured. Blood pressure, pulse and BMI were checked using tools that have been 
calibrated by the Calibration and Testing Laboratory of Universitas Ahmad Dahlan. RBS and 
HbA1c measurements were performed by the Public Health Center laboratory with 5010 
spectrophotometer. The brief procedure of HbA1c measurement was as follows: 10 µL of blood 
plasma was put into the reaction tube, and then added with 1 mL of glucose reagent. After 10 
minutes, the patients’ blood glucose plasma was measured with a 5010 spectrophotometer. The 
results were then used to calculate the HbA1c value by the following formula: 
 
HbA1c = (Glucose Plasma  + 77.3) / 35.6 
Demographic characteristics were presented descriptively. The mean comparison test was 
performed on the measurement data of blood pressure, pulse, BMI, serum glucose level, and 
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HbA1c levels on day 0 and day 21 with one-way ANOVA using SPSS free edition software 
(SPSS version 16) with 95% confidence level.  
 
3. Result and Discussion 
3.1. Characteristics of research subjects 
Four hundred and one of  diabetes mellitus patients and 615 hypertensive patients who 
underwent treatment at Jetis I Public Health Center, Bantul, based on the recommendation of 
the treating physicians, 120 prospective subjects fulfilled the inclusion criteria.  
Table 1. Characteristics of research subjects 
Characteristics Treatment Group p-
value Placebo group Group 1 Group 2 
Subjects n = 33 n = 33 n = 33 
Gender 
Men 9 7 7 0.802 
Women 24 26 26 
Age (years) 
≤55 years old 14 14 15 0.582 
> 56 years old 19 16 18 
Education 
≤Junior HS 19 21 19 0.999 
Senior HS ≤ 14 12 14 
Occupation 
Civil servants 1 0 3 0.141 
Entrepreneur 5 3 5 
Farmers 4 3 5 
Private Sector 1 2 2 
Labor 5 7 4 
Fishermen 1 0 4 
Unemployed 11 11 5 
etc. 5 7 5 
Marital Status 
Married 32 32 33 0.608 
Single 1 1 0 
 
All prospective subjects were then gathered and briefed and asked to sign the informed 
consent, but only 112 patients were willing to become research subjects. Demographic and 
clinical characteristics are presented in table 1 & 2. Table 1 and 2 shows that based on gender, 
age, education, occupation, marital status and therapy type, there were no differences among 
groups (p>0.05). Most of the subjects were junior high school female graduates and aged over 
50 years old. 
Most subjects received more than one drug therapy, with most patients receiving a 
combination therapy of 1 OHO and 1 antihypertensive drugs, followed by patients with a single 
OHO drug, patients with two OHO drugs, and patients with 2 OHO drugs and 1 
antihypertensive medication. 
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Table 2. Type of drug therapy prescribed by doctors 
Type of single and combination therapy 
for patients at risk of metabolic syndrome 
Treatments Group p-value 
Placebo 
group 
Group 1 Group 2 
(n = 33) (n = 33) (n = 33) 
1 diabetes drug 6 11 6 0.333 
1 hypertensive drug 0 0 1 
1 dyslipidemia drug 0 1 0 
2 diabetes drugs 5 6 6 
2 hypertensive drugs 0 1 0 
3 diabetes drugs 0 0 1 
1 diabetes drug +1 hypertensive drug 14 4 7 
1 diabetes drug + 1 dyslipidemia drug 0 1 1 
1 diabetes drug + 2 hypertensive drugs 0 3 1 
2 diabetes drugs + 1 hypertensive drug 5 3 4 
2 diabetes drugs + 1 dyslipidemia drug  1 0 0 
2 diabetes drugs + 2 hypertensive 1 3 3 
3 diabetes drugs + 1 hypertensive drugs 1 0 0 
1 diabetes drug + 1 hypertensive drug + 1 
dyslipidemia drug 
0 0 1 
1 diabetes  drug + 1 hypertensive drug + 2 
dyslipidemia drug 
0 0 1 
2 diabetes drugs +1 hypertensive drug + 1 
dyslipidemia drug 
0 0 1 
 
3.2. Measurement results of clinical conditions and HbA1c levels on day 0 
Subjects’ clinical conditions (blood pressure, pulse rate, BMI, glucose serum level  and HbA1c 
on day 0 (before treatment) are shown in Table 3. 
 
Table 3. Blood pressure, pulse, BMI, serum glucose level and HbA1c on day 0 
Vital Signs 
Treatment Group 
p-
value 
Placebo group Group 1 Group 2 
(n = 33) (n = 33) (n = 33) 
Systolic (mmHg) 142.48± 16.42 141.73±16.84 143.64±18.63 0.903 
Diastolic (mmHg) 79.76± 7.005 80.52±9.138 81.09±9.531 0.821 
Pulse 89.39± 9.997 89.33±10.764 90.82±11.246 0.816 
BMI (Kg/m
2
) 24.15± 4.103 23.76±4.346 24.53±3.8 0.749 
Serum Glucose Level (mg/dL) 266.93±123.99 233.66±100.94 273.03±126.40 0.070 
HbA1c (%) 9,300± 8.057 8.56 ± 2.777 9.34 ± 3.295 0.524 
 
The results of vital signs and HbA1c measurement on day 0 show that there was no 
significant difference (p> 0.05) in blood pressure, pulse, BMI, glucose serum level, and HbA1c 
levels prior to BCSO administration. Before the treatment, subjects’ mean of blood glucose and 
HbA1c levels exceeded the normal values of RBS with >200 mg/dL and HbA1c with >7%. The 
mean systolic blood pressure (SBP) also exceeded the normal value with >140 mmHg, but the 
mean diastolic blood pressure (DBP) was relatively normal with <90 mmHg [8]. 
3.3. Measurement results of clinical condition and HbA1c on day 21 
The measurement results of clinical conditions (blood pressure, pulse rate, BMI, blood glucose 
serum) and HbA1c levels on  day 21 are presented in Table 4. 
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Table 4. Measurement results of clinical conditions and HbA1c levels on day 21 
Vital Signs 
Treatments Group 
p-
value 
Placebo group Group 1 Group 2 
(n = 33) (n = 33) (n = 33) 
Systolic (mmHg) 138.66±13.170 136.10±15.946 139.81±17.662 0.636 
Diastolic (mmHg) 75.31±8.476 79.52±17.160 80.87±9.804 0.182 
Pulse 89.66±11.085 90.26±10.155 93.87±14.440 0.330 
BMI (Kg/m
2
) 24.55±4.363 24.04±4.393 25.31±3.881 0.493 
Serum glucose level (mg/dL) 270.31±80.324 190.19±88.304 199.61±91.172 0.001 
HbA1c (%) 9.60±2.260 
ab
 7.44±2,487 
c
 7.51±2.492 0.001 
a
 There was a significant difference between the placebo group and group 1  
b
 There was a significant difference between the placebo group and group 2 
c
 There was no significant difference between  group 1 and group 2. 
 
Table 4 shows that after 20 days of BCSO treatment, there was no difference in blood 
pressure, pulse rate, and BMI between the treatment groups, with significance value of 
p>0.05. It shows that the BCSO administration can lower blood pressure to the target level 
defined for patients with diabetes mellitus by the American Diabetes Association (ADA) and 
the American Heart Association (AHA) [8], i.e. <140/90 mmHg. However, the result has not 
met the therapeutic target defined by the International Diabetes Mellitus Federation (IDF) 
(2006) that recommends a blood pressure target of <135/85 mmHg. There has been a decrease 
in the mean TDS, i.e. TDS <140 mmHg, although not statistically significant (p> 
0.05). Research data also shows that there is no change in average pulse in all groups, and the 
mean pulse is in accordance with the normal target range according to the American Heart 
Association (60-100x/min). The average BMI in the three groups after the treatment was 
relatively similar (p>0.05), categorized as non-obese according to the American Heart 
Association [8]. The results of this study are not entirely consistent with previous studies, which 
stated that administering black cumin seed extract (BCSE) with a dose of 500 mg for 8 weeks 
could lower blood pressure in patients with metabolic syndrome [21]. Differences in terms of 
intervention timing, intervention type, subjects’ initial condition, and research setting contribute 
to the differences in clinical outcomes.  Provided an 8-week BCSE intervention for patients with 
metabolic syndrome in hospitals, whereas this study provided a 20-day BCSO intervention in 
patients at risk of metabolic syndrome in Public Health Center [21]. 
The results showed that there was an average decrease of RBS and HbA1c levels after BCSO 
treatment for 20 days, and there was a difference in the average values of RBS and HbA1c 
levels among three treatment groups (p<0.01). There were significant differences in HbA1c and 
RBS values between the control group and treatment group 1 and treatment group 2 (p<0.01), 
but there was no significant difference between treatment group 1 and treatment group 2 (p> 
0.05). However, despite a decline in the mean HbA1c value of the treatment groups, the results 
are not yet capable of reaching the targets defined by the American Diabetes 
Association (<7%). These results are in line with previous studies, which revealed that the 
administration of BS extract with a dose of 500 mg or BS oil with a dose of 2.5 mL/day for 8 
weeks could decrease HbA1c and RBS levels in patients with metabolic syndrome [21] . 
BCSO can lower the HbA1c value because it increases insulin production, decreases insulin 
resistance, stimulates cellular activity, and decreases intestinal insulin absorption [22]. High 
thymoquinone content in BCSO has antioxidant effect that can decrease oxidative stress to 
prevent further cell damage [22, 23]. Consumpsion of 2 g/day of black cuminseed combined 
with oral hypoglycemic drugs can improve the effectiveness of endogenous antioxidant and 
enzyme therapy [24]. High blood glucose and HbA1c levels have been shown to be associated 
with increased incidence of death and cardiovascular disease [25]. Furthermore, the antioxidant 
diet has been shown to inhibit degenerative processes, reduce risk of and death from 
cardiovascular disease, and prolong life [16, 26-27]. 
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4. Conclusion 
Black cumin seed oil treatment with doses of 1.5 and 3 mL/day for 20 days in patients at risk of 
metabolic syndrome affects HbA1c activity (p<0.05) by reducing its level. 
Phase III Clinical Trial of BCSO needs to be done in patients at risk of metabolic syndrome 
with longer administration time as an attempt to obtain phytopharmaca (phytomedicines) for 
secondary prevention of cardiovascular disease incidence in primary care. 
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